Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Wednesday the launch of its Nitazoxanide Tablets, 500 mg, the generic version of the reference listed drug Alinia.
Nitazoxanide is used to treat diarrhoea caused by certain parasites.
US annual sales for Nitazoxanide Tablets are approximately USD36.1m, based on the December 2024 moving annual total IQVIA data.
This launch expands ANI's portfolio and provides an alternative treatment option in the market.
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets